Ascendis Pharma A/S
ASND
$223.82
-$3.59-1.58%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 55.41% | 292.83% | 362.94% | 2.05% | 25.05% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.41% | 292.83% | 362.94% | 2.05% | 25.05% |
| Cost of Revenue | 83.77% | 112.23% | 189.22% | 124.34% | -28.64% |
| Gross Profit | 52.92% | 336.21% | 444.12% | -8.43% | 33.89% |
| SG&A Expenses | 89.66% | 72.70% | 52.62% | 46.67% | 24.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.25% | 39.41% | 31.45% | 37.12% | -1.43% |
| Operating Income | 580.85% | 112.09% | 58.10% | -105.56% | 101.04% |
| Income Before Tax | 21.99% | 37.86% | 66.18% | 29.43% | 54.35% |
| Income Tax Expenses | 590.14% | 277.09% | 1,671.68% | -58.99% | -81.45% |
| Earnings from Continuing Operations | 4.72% | 34.62% | 62.54% | 30.00% | 56.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.72% | 34.62% | 62.54% | 30.00% | 56.16% |
| EBIT | 580.85% | 112.09% | 58.10% | -105.56% | 101.04% |
| EBITDA | 143.30% | 117.29% | 60.20% | -116.30% | 104.58% |
| EPS Basic | 6.65% | 38.08% | 64.47% | 33.65% | 58.52% |
| Normalized Basic EPS | 2.09% | 41.15% | 67.92% | 33.12% | 56.82% |
| EPS Diluted | 6.73% | 38.08% | 64.47% | 33.65% | 58.48% |
| Normalized Diluted EPS | 2.09% | 41.15% | 67.83% | 33.12% | 56.82% |
| Average Basic Shares Outstanding | 2.07% | 5.60% | 5.42% | 5.51% | 5.70% |
| Average Diluted Shares Outstanding | 2.07% | 5.60% | 5.11% | 5.51% | 5.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |